Trifluoroacetic acid → HCID 178471612, 화합물

HRID 852862노트

반응식

HRID 852862 반응식
[CH2:1]([O:3][C:4](=[O:41])[CH:5]=[CH:6][CH:7]([NH:33]C(OC(C)(C)C)=O)[CH2:8][C:9]1[N:10]=[CH:11][N:12](C(C2C=CC=CC=2)(C2C=CC=CC=2)C2C=CC=CC=2)[CH:13]=1)[CH3:2].C(O)(C(F)(F)F)=O>>[CH2:1]([O:3][C:4](=[O:41])[CH:5]=[CH:6][CH:7]([NH2:33])[CH2:8][C:9]1[N:10]=[CH:11][NH:12][CH:13]=1)[CH3:2]

참가 물질

3

반응물 2

HCID 6422Trifluoroacetic acidHCID 694162234-tert-Butoxycarbonylamino-5-(1-trityl-1H-imidazol-4-yl)-pent-2-enoic acid ethyl ester

생성물 1

HCID 178471612HCID 178471612, 화합물수율 53%

실험 절차

A representative procedure is as follows. 4-tert-Butoxycarbonylamino-5-(1-trityl-1H-imidazol-4-yl)-pent-2-enoic acid ethyl ester (100 mg, 0.181 mmol) was stirred with TFA (5 mL) overnight under an atmosphere of argon. The TFA was removed and the residue triturated with Et2O. The remaining solid was subject to preparative reverse phase HPLC (30% B to 100% B over 20 min) to yield after lyophilization a gum (20 mg, 53%). 1H NMR (300 MHz, d6-DMSO) δ 1.19 (3H, t, J=7.02), 3.19 (2H, br s), 4.12 (2H, q, J=7.02), 4.33 (1H, m), 6.09 (1H, d, J=15.87), 6.76 (1H, dd, J=7.14, 15.87), 7.49 (1H, br s), 9.01 (1H, br s). 13C NMR (d6-DMSO) δ 164.76, 141.83, 134.64, 127.39, 125.08, 118.09, 60.58, 50.03, 27.57, 14.06.

후처리

  1. customThe TFA was removed
  2. customthe residue triturated with Et2O
  3. customwas subject to preparative reverse phase HPLC (30% B to 100% B over 20 min)

출처 및 근거

ORD 기록
ord-27124b55238d4ea281bf2ea94a942cda
출처 데이터셋
uspto-grants-2007_08
특허 번호
US07253194B2

반응 노트

불러오는 중…